Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.

Executive Summary

Barr's patent challenge against Pfizer's Estrostep Fe is the generic company's latest step in attempting to expand its oral contraceptives franchise.

You may also be interested in...



Allegra Growth Expected At 20% Annually; Generic Impact Possible In 2004

Aventis expects sales of its antihistamine Allegra (fexofenadine) to grow at a rate of about 20% annually, although generic competition could begin to have an impact beginning in 2004

Allegra Growth Expected At 20% Annually; Generic Impact Possible In 2004

Aventis expects sales of its antihistamine Allegra (fexofenadine) to grow at a rate of about 20% annually, although generic competition could begin to have an impact beginning in 2004

Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry

Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement

Related Content

UsernamePublicRestriction

Register

PS038373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel